Oncology Archives - Page 16 of 23

Work productivity in HER2 positive breast cancer: A comparison of patients across stages of early and metastatic disease

Authors: M Verrill, P Schmid, J Retzler, A B Smith, C J Bottomley, S Dando, I Tran, I Leslie, A M Wardley Published: Value in Health, 2017 View publication Objectives While the...

The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: a retrospective study

Authors: T Talbot, A Dangoor, R Shah, J Naik, D Talbot, J F Lester, R Cipelli, M Hodgson, A Patel, M Summerhayes, T Newsom-Davis Published: Lung cancer, 2017 View publication Objectives To...

NICE guidance on the use of carmustine wafers in high grade gliomas: A national study on variation in practice

Authors: S J Price, I R Whittle, K Ashkan, P Grundy, G Cruickshank Published: Br J Neurosurg, 2012 View publication Background Multidisciplinary team (MDT) working in oncology aims to improve outcomes for...

Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: a model based analysis

Authors: V Daniels, K Saxena, C Roberts, S Kothari, S Corman, L Yao, L Niccolai Published: Vaccines, 2021 View publication Abstract The coronavirus disease 2019 (COVID-19) pandemic has significantly affected utilization of...

Economic value of lost productivity attributable to human papillomavirus cancer mortality in the United States

Authors: M Priyadarshini, V S Prabhu, S J Snedecor, S Corman, B J Kuter, C Nwankwo, D Chirovsky, E Myers Published: Frontiers in Public Health, 2021 View publication Objectives To estimate years...

Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States

Authors: C L Simons, D Malone, M Wang, G A Maglinte, T Inocencio, S W Wade, C Bennison, B Shah Published: Journal of Medical Economics, 2021 View publication Aims The objective of...

What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell carcinoma

Authors: S L Klijn, E Fenwick, S Kroep, K Johannesen, B Malcolm, M Kurt, C Kiff, J Borrill Published: PharmacoEconomics, 2020 View publication Background The immuno-oncologic (IO) mechanism of action may lead...

Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: a large retrospective cohort analysis

Authors: N Joshi, H Kale, S Corman, T Wert, K Hill, A M Zeidan Published: Clinical Lymphoma Myeloma Leukemia, 2020 View publication Background Suboptimal use of hypomethylating agents (HMAs) among higher-risk myelodysplastic...

Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis

Authors: S Corman, N Joshi, T Wert, H Kale, K Hill, A M Zeidan Published: Clinical Lymphoma, Myeloma Leukemia, 2020 View publication Background Recent data suggest significant underutilization of hypomethylating agents (HMAs)...